Prime Medicine, Inc. (PRME) fundamentals score
Prime Medicine is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 4.7 out of 10, Weak long-term fundamentals
- Growth: 6.8/10
- Profitability: 3.3/10
- Financial health: 5.8/10
- Earnings quality: 5.6/10
- Valuation: 1.5/10
Scores are calculated from Prime Medicine, Inc.’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10